What patellar tendinopathy and enthesopathy actually mean

Pain at the front of the knee, just below the kneecap, that worsens with running, jumping, or prolonged sitting is a familiar pattern for anyone who has been given a diagnosis of patellar tendinopathy — sometimes called jumper's knee. The condition is degenerative rather than acutely inflammatory: collagen fibres within the patellar tendon lose their normal organisation at the inferior pole of the patella, accompanied by reactive neo-vascularisation and a failure of the tendon's usual repair process. The term tendinitis is now largely set aside in favour of tendinopathy precisely to reflect this degenerative rather than inflammatory character.

Enthesopathy describes a related but distinct process: degenerative or inflammatory change at the enthesis, the point where the tendon meets bone. On ultrasound this typically appears as hypoechoic change and increased tendon thickness at the inferior patellar pole. The two diagnoses often coexist, though the enthesopathic component — the bone-tendon junction itself — carries slightly different implications for some treatment choices, particularly surgical ones.

Research confirms that patellar tendinopathy pain is generated locally within the diseased tendon tissue rather than driven by central sensitisation; studies find no difference in conditioned pain modulation or temporal summation between symptomatic athletes and healthy controls. The clinical implication is straightforward: structured, tissue-directed rehabilitation is scientifically grounded, not merely empirical tradition.

Exercise rehabilitation as the primary treatment

Structured loading is the engine of recovery in patellar tendinopathy — not simply 'rest and see'. Exercise drives the collagen remodelling that the diseased tendon cannot achieve on its own, and the evidence base behind this is now substantial.

The two most established approaches are eccentric training and heavy slow resistance training (HSRT). Eccentric loading — slow, controlled knee bends under body weight or added resistance, lowering into the load rather than lifting out of it — has long been considered the gold standard for stimulating collagen fibre reorganisation within the affected portion of the tendon. HSRT builds on this by using bilateral or unilateral slow-tempo knee extension and squat movements under progressively heavier loads, typically three seconds down and three seconds up. Both methods share the same principle: deliberate, controlled mechanical stress applied over weeks to months, not days.

For patients who cannot tolerate high joint or tendon loads — including older adults, those returning from injury, or anyone with concurrent knee problems — low-load blood-flow restriction training (LL-BFRT) is a well-supported alternative. A 2025 randomised controlled trial (n = 36) found that LL-BFRT produced outcomes equivalent to HSRT on both pain and VISA-P function scores at 12 and 52 weeks. The technique uses a cuff to partially restrict venous return, allowing meaningful muscle and tendon stimulus at a fraction of the usual load.

A 2025 Delphi consensus from UK Defence Rehabilitation — 28 agreed recommendations — reinforces that exercise rehabilitation is the primary management strategy and should anchor all treatment plans; adjuncts such as injections or shockwave therapy are considered on a case-by-case basis only, and do not replace loading programmes.

Patience is genuinely required. Load must be progressed in line with symptoms, and meaningful improvement typically takes months. Five-year follow-up data, discussed in the outcomes section below, confirm that the majority of athletes do recover with physiotherapy alone — but a meaningful minority do not fully regain their pre-injury level, which is worth acknowledging from the start of any rehabilitation plan.

Shockwave therapy and dry needling as adjuncts

Two physical adjuncts — extracorporeal shockwave therapy (ESWT) and dry needling — are commonly added to a loading programme when symptoms remain troublesome despite adequate exercise, or when recovery is slower than expected.

Focused ESWT has the stronger evidence base, and the clinical distinction is worth spelling out. Most adjuncts reduce pain; ESWT appears to change the tendon itself. A 2025 prospective cohort of 21 recreational athletes receiving focused ESWT over four weekly sessions recorded a significant reduction in tendon diameter and measurable improvement in collagen fascicle organisation on ultrasound at three months, alongside meaningful gains in both NRS pain scores and VISA-P function scores. That combination — structural remodelling and symptomatic improvement together — sets ESWT apart from purely analgesic adjuncts. For patients with the enthesopathic variant, where bony change is present at the inferior patellar pole attachment, focused shockwave has specific relevance: it has been studied directly in enthesopathic presentations and represents a logical choice when the bone-tendon junction is implicated.

Dry needling occupies a different position in the evidence hierarchy. It has featured as an active comparator arm — not a sham control — in randomised trials comparing it with PRP, which provides reasonable support for a genuine therapeutic effect rather than a placebo response. It is generally considered appropriate for milder or earlier-stage presentations where a more invasive injection approach is not yet warranted.

Both modalities work alongside a structured loading programme; the rehabilitation must continue throughout and beyond any adjunct course, or gains are unlikely to be maintained.

Injection options for persistent or recalcitrant cases

When a structured loading programme — with or without shockwave therapy — has not produced adequate recovery after several months, injection therapy enters the picture. The most evidence-supported option at this stage is platelet-rich plasma (PRP).

The established protocol for chronic recalcitrant cases involves three ultrasound-guided intratendinous injections of 5 mL PRP, spaced approximately two weeks apart. Outcomes data from medium-term follow-up studies — extending to four years — show stable clinical improvement in patients who had not responded to conservative measures alone. Crucially, the benefit appears to go beyond symptom relief: prospective series have documented normalisation of tendon architecture on MRI alongside resolution of pain and improved function, suggesting that PRP supports genuine tissue remodelling rather than simply masking the problem. Mechanistically, murine models indicate that PRP elevates vascularity within the tendon in the first two to four weeks and improves collagen arrangement by eight weeks — a timeline that helps explain why clinical gains tend to emerge gradually after the injection course.

Polidocanol, a sclerosing agent that targets the pathological neo-vascularisation associated with tendinopathy, is described in the literature as a minimally invasive bridging option for patients who have not recovered with exercise alone and are weighing whether to proceed to surgery.

By contrast, corticosteroid injections are not recommended for patellar tendinopathy. Their risks in this context are specific and well-characterised: reduced collagen synthesis, tendon atrophy, and a meaningfully raised risk of tendon rupture. Short-term pain relief can also produce a false sense of recovery that encourages premature loading — precisely the conditions most likely to accelerate structural damage. The evidence base does not support their routine use here, even though corticosteroids have an accepted role in other knee conditions such as inflammatory bursitis or synovitis.

When surgery is appropriate and what it involves

Around one in five people with patellar tendinopathy will not recover sufficiently with conservative measures and eventually reach the question of whether surgery is appropriate. The accepted threshold — informed by clinical consensus and supported in the systematic literature — is three to six months of structured, progressive conservative management that has failed to produce adequate improvement. That window matters: it is long enough to give rehabilitation, shockwave therapy, and injection options a fair trial, and short enough to avoid indefinite delay for those who genuinely need operative intervention.

The arthroscopic procedure: what each step addresses

The preferred surgical approach is arthroscopic debridement — a minimally invasive technique carried out through small portals under camera guidance. It typically combines four components, each targeting a distinct aspect of the pathology:

• Osteoplasty of the distal patellar pole — reshaping the inferior bony tip of the patella to address the enthesopathic changes at the bone-tendon junction discussed earlier in this article
• Debridement of the degenerate proximal tendon — removing the structurally compromised tissue that has failed to remodel
• Hoffa fat pad clearance — addressing inflammation and impingement in the fat pad immediately below the tendon
• Cauterisation of pathological neo-vessels — ablating the abnormal blood vessel in-growth that accompanies chronic tendinopathy

In a published series of 11 high-level athletes who had not responded to prolonged conservative management, Lysholm scores improved from a mean of 49.9 to 92.5, and VISA-P scores from 41.2 to 86.8, by the tenth postoperative week. All participants returned to sport by week twelve; mean follow-up was 17.4 months. A 2025 systematic review confirms that arthroscopic debridement is safe and effective, with patient satisfaction rates of approximately 90%.

Honest caveats on the evidence

These results are encouraging, but long-term randomised controlled trial data comparing arthroscopic and open techniques — or comparing arthroscopic debridement with versus without distal pole resection — remain limited. Patient selection and surgeon experience carry real weight in determining outcomes, and the scores above should be read as indicative of what well-selected cases can achieve, not as a universal promise.

Long-term outlook and getting the right assessment

The five-year follow-up data sets honest expectations rather than reassuring ones. Most people with patellar tendinopathy recover with structured care — but recovery is not universal, and those who remain unrecovered at five years typically carried higher baseline pain and functional limitation from the outset. That pattern points to something actionable: early, accurate diagnosis and a promptly started loading programme are among the strongest predictors of a good outcome, not simply good housekeeping.

When initial physiotherapy has not moved things forward, repeating the same programme is rarely the answer. A consultant-led review — rather than another self-directed exercise course — can establish whether the diagnosis is fully characterised, whether enthesopathic bony change at the inferior patellar pole has been imaged, and whether the rational next step is an adjunct, an injection course, or surgical referral. MRI has a specific role at this stage: it quantifies the degree of tendon degeneration, confirms involvement at the bone-tendon junction, and shifts the clinical conversation from symptom-led to pathology-led when procedural decisions are being weighed — a different purpose from imaging at first presentation.

For patients who have been managing without clear progress, Lincolnshire Knee — part of the MSK Doctors group — accepts patients without a GP referral, with assessments at Sleaford and Grantham covering diagnostic imaging and pathway planning. The goal is to establish precisely where a patient sits in the conservative-to-surgical spectrum, so the next step is guided by the evidence rather than arrived at by elimination.

1. [1] Endogenous pain modulation is not different in basketball or volleyball athletes with patellar tendinopathy compared to asymptomatic athletic controls. (2025). https://doi.org/10.1016/j.msksp.2025.103280 https://doi.org/10.1016/j.msksp.2025.103280
2. [2] UK Defence Rehabilitation consensus agreement for the conservative management of Achilles and patellar tendinopathy: a modified Delphi approach. (2025). https://doi.org/10.1136/military-2024-002893 https://doi.org/10.1136/military-2024-002893
3. [3] Effect of Low-Load Blood-Flow Restricted Training Versus Heavy Slow Resistance Training in Unilateral Patellar Tendinopathy: A Randomized Clinical Trial. (2025). https://doi.org/10.1111/sms.70186 https://doi.org/10.1111/sms.70186
4. [4] Long-term Prognosis of Athletes With Patellar Tendinopathy Receiving Physical Therapy: Patient-Reported Outcomes at 5-Year Follow-up. (2025). https://doi.org/10.1177/03635465251336466 https://doi.org/10.1177/03635465251336466
5. [5] ESWT is able to change macromorphological and micromorphological parameters in patellar tendinopathy: a prospective cohort study. (2025). https://doi.org/10.1097/JS9.0000000000002351 https://doi.org/10.1097/JS9.0000000000002351
6. [6] Platelet-rich plasma (PRP) accelerates murine patellar tendon healing through enhancement of angiogenesis and collagen synthesis. (2020). https://doi.org/10.1186/s40634-020-00267-1 https://doi.org/10.1186/s40634-020-00267-1